DESCRIPTION SECTION.


DESCRIPTION:. Sodium Sulfacetamide Medicated Pads 10% contain 10% solution of sodium sulfacetamide on textured pad. Each gram of medicated solution contains 100 mg sodium sulfacetamide, purified water, sodium EDTA, sodium thiosulfate and urea 1 0%). Sodium Sulfacetamide Medicated Pads are greaseless and leave no residue when applied to the skin.Sodium sulfacetamide is sulfonamide with antibacterial activity. Chemically, sodium sulfacetamide is C8H9N2Na03SoH2O, with molecular weight of 254.24. Chemically it is acetamide, N- [(4 aminophenyl) sulfonyl]-, monosodium salt and monohydrate, with the following structural formula:. Structural Formula.

DOSAGE & ADMINISTRATION SECTION.


DOSAGE AND ADMINISTRATION:. Gently apply Sodium Sulfacetamide Medicated Pads to the affected areas to times daily or as directed by physician until the infection has cleared.

DRUG INTERACTIONS SECTION.


Drug Interactions:Sodium Sulfacetamide Medicated Pads are incompatible with silver preparations.

CLINICAL PHARMACOLOGY SECTION.


CLINICAL PHARMACOLOGY:. Sodium sulfacetamide exerts bacteriostatic effect against sulfonamide-sensitive gram-positive and gram-negative micro-organism including P. acne commonly isolasted from secondary cutaneous pyogenic infections.The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid ( ABA), an essential component for bacterial growth. While absorption through intact skin in humans has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine largely unchanged. The biological half-life has variously been reported as o 12.8 hours.

ADVERSE REACTIONS SECTION.


ADVERSE REACTIONS:. Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity, which progressed to syndrome resembling systemic lupus erythematosus; in one case fatal outcome has been reported (see WARNINGS).

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.


Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on Sodium Sulfacetamide Medicated Pads.

CONTRAINDICATIONS SECTION.


CONTRAINDICATIONS:. Sodium Sulfacetamide Medicated Pads are contraindicated in persons with known or suspected hypersensitivity to sulfonamides or to any of the ingredients of the preparation. Sodium Sulfacetamide Medicated Pads are not to be used by patients with kidney disease.

GENERAL PRECAUTIONS SECTION.


General: Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. Hypersensitivity reactions may recur when sulfonamide is readministered, irrrespective of the route of administration, and cross hypersensitivity between different sulfonamides may occur. If Sodium Sulfacetamide Medicated Pads produce signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded, or severely burned areas. Under these circumstances, potentially any of the adverse effects produced by the systemic administration of these agents could occur, and appropriate observations and laboratory determinations should be performed.

HOW SUPPLIED SECTION.


HOW SUPPLIED:. Sodium Sulfacetamide Medicated Pads NDC 0168-0484-01 contain 30 Foil Pouches, each with single-use medicated pad (2.5 mL each).Store at 15-30 (59-86 F). Protect from freezing.Sodium Sulfacetamide Medicated Pads may darken after prolonged storage. Slight discoloration does not impair the efficacy or safety of the product.Manufactured for: E. FOUGERA CO.A division of Nycomed US Inc., Melville New York 11747Manufactured by: Pegasus Laboratories, Inc., Pensacola, FL 32514IL302A R3/09.

INDICATIONS & USAGE SECTION.


INDICATIONS AND USAGE:. Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

INFORMATION FOR PATIENTS SECTION.


INFORMATION FOR PATIENTS:. Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. Patients should discontinue the use of Sodium Sulfacetamide Medicated Pads if the condition becomes worse, or if rash develops in the area being treated or elsewhere. Sodium Sulfacetamide Medicated Pads also should be discontinued promptly and the physician notified if any arthritis, fever, or sores in the mouth develop.. Drug Interactions:Sodium Sulfacetamide Medicated Pads are incompatible with silver preparations.. Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on Sodium Sulfacetamide Medicated Pads.. Pregnancy Category C: Animal reproduction studies have not been conducted with Sodium Sulfacetamide Medicated Pads. It also is not known whether Sodium Sulfacetamide Medicated Pads can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide Medicated Pads should be used by pregnant woman only if clearly needed.. Nursing Mothers: It is not known whether this drug is excreted in human milk following topical use of Sodium Sulfacetamide Medicated Pads. Because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide Medicated Pads are administered to nursing woman.. Pediatric Use: Safety and effectiveness in children below the age of 12 years have not been established.

NURSING MOTHERS SECTION.


Nursing Mothers: It is not known whether this drug is excreted in human milk following topical use of Sodium Sulfacetamide Medicated Pads. Because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide Medicated Pads are administered to nursing woman.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.


PACKAGE LABEL PRINCIPAL DISPLAY PANEL CARTON 30 CT. NDC 0168-0484-0130 Foil Pouches (2.5 mL each)Fougera(R) SODIUM SULFACETAMIDEMedicated Pads 10%In Urea VehicleFor Topical Use OnlyFor dermatologic use only not for ophthalmic useContains: 30 Foil Pouches, each with single-use medicated pad (2.5 mL each)Rx onlyE. FOUGERA CO.A division of Nycomed US Inc.Melville, New York 11747. PACKAGE LABEL PRINCIPAL DISPLAY PANEL CARTON 30 CT.

PEDIATRIC USE SECTION.


Pediatric Use: Safety and effectiveness in children below the age of 12 years have not been established.

PRECAUTIONS SECTION.


PRECAUTIONS:. General: Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. Hypersensitivity reactions may recur when sulfonamide is readministered, irrrespective of the route of administration, and cross hypersensitivity between different sulfonamides may occur. If Sodium Sulfacetamide Medicated Pads produce signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded, or severely burned areas. Under these circumstances, potentially any of the adverse effects produced by the systemic administration of these agents could occur, and appropriate observations and laboratory determinations should be performed.

PREGNANCY SECTION.


Pregnancy Category C: Animal reproduction studies have not been conducted with Sodium Sulfacetamide Medicated Pads. It also is not known whether Sodium Sulfacetamide Medicated Pads can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide Medicated Pads should be used by pregnant woman only if clearly needed.

SPL UNCLASSIFIED SECTION.


in Urea VehicleFOR DERMATOLOGIC USE ONLYRx onlyNOT FOR OPHTHALMIC USE.

WARNINGS SECTION.


WARNINGS:. Although rare, sensitivity o sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported.